Viridian Therapeutics, Inc./DE Cost of Revenue
Viridian Therapeutics, Inc./DE (VRDN) reported Cost of Revenue of $2.55 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-24.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2017-03-24
- Viridian Therapeutics, Inc./DE cost of revenue for the quarter ending 2016-12-31 was $692.00K, a 51.75% increase year-over-year.
- Viridian Therapeutics, Inc./DE cost of revenue for the quarter ending 2016-09-30 was $599.00K, a 3.81% increase year-over-year.
- Viridian Therapeutics, Inc./DE cost of revenue for the quarter ending 2016-06-30 was $628.00K, a 7.37% decline year-over-year.
- Viridian Therapeutics, Inc./DE cost of revenue for the quarter ending 2016-03-31 was $629.00K, a 17.24% decline year-over-year.
- Viridian Therapeutics, Inc./DE cost of revenue for fiscal 2016 was $2.55M, a 3.07% increase from fiscal 2015.
- Viridian Therapeutics, Inc./DE cost of revenue for fiscal 2015 was $2.47M, a 26.56% decline from fiscal 2014.
- Viridian Therapeutics, Inc./DE cost of revenue for fiscal 2014 was $3.37M, a 21.17% increase from fiscal 2013.
- Viridian Therapeutics, Inc./DE cost of revenue for fiscal 2013 was $2.78M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 3 month as first filed | Cost of Revenue 6 month | Cost of Revenue 6 month as first filed | Cost of Revenue 9 month | Cost of Revenue 9 month as first filed | Cost of Revenue 12 month | Cost of Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $692.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $1.29M derived: sum of 2 quarters · filed 2017-03-24 | $1.92M derived: sum of 3 quarters · filed 2017-03-24 | $2.55M 10-K · filed 2017-03-24 | ||||
| 2016-09-30 | $599.00K 10-Q · filed 2016-10-26 | $1.23M derived: sum of 2 quarters · filed 2016-10-26 | $1.86M 10-Q · filed 2016-10-26 | $2.31M derived: sum of 4 quarters · filed 2017-03-24 | ||||
| 2016-06-30 | $628.00K 10-Q · filed 2016-08-15 | $1.26M 10-Q · filed 2016-08-15 | $1.71M derived: sum of 3 quarters · filed 2017-03-24 | $2.29M derived: sum of 4 quarters · filed 2017-03-24 | ||||
| 2016-03-31 | $629.00K 10-Q · filed 2016-05-16 | $1.08M derived: sum of 2 quarters · filed 2017-03-24 | $1.66M derived: sum of 3 quarters · filed 2017-03-24 | $2.34M derived: sum of 4 quarters · filed 2017-03-24 | ||||
| 2015-12-31 | $456.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $1.03M derived: sum of 2 quarters · filed 2017-03-24 | $1.71M derived: sum of 3 quarters · filed 2017-03-24 | $2.47M 10-K · filed 2017-03-24 | ||||
| 2015-09-30 | $577.00K 10-Q · filed 2016-10-26 | $1.25M derived: sum of 2 quarters · filed 2016-10-26 | $2.02M 10-Q · filed 2016-10-26 | $2.80M derived: sum of 4 quarters · filed 2016-10-26 | ||||
| 2015-06-30 | $678.00K 10-Q · filed 2016-08-15 | $1.44M 10-Q · filed 2016-08-15 | $2.22M derived: sum of 3 quarters · filed 2016-08-15 | $3.12M derived: sum of 4 quarters · filed 2016-08-15 | ||||
| 2015-03-31 | $760.00K 10-Q · filed 2016-05-16 | $1.54M derived: sum of 2 quarters · filed 2016-05-16 | $2.44M derived: sum of 3 quarters · filed 2016-05-16 | $3.40M derived: sum of 4 quarters · filed 2016-05-16 | ||||
| 2014-12-31 | $781.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-21 | $1.68M derived: sum of 2 quarters · filed 2016-03-21 | $2.63M derived: sum of 3 quarters · filed 2016-03-21 | $3.37M 10-K · filed 2016-03-21 | $3.24M 10-K · filed 2015-03-27 | |||
| 2014-09-30 | $900.00K 10-Q · filed 2015-11-13 | $871.52K 10-Q · filed 2014-11-14 | $1.85M derived: sum of 2 quarters · filed 2015-11-13 | $2.58M 10-Q · filed 2015-11-13 | $2.33M 10-Q · filed 2014-11-14 | $3.25M derived: sum of 4 quarters · filed 2015-11-13 | ||
| 2014-06-30 | $954.00K 10-Q · filed 2015-08-14 | $675.73K 10-Q · filed 2014-08-14 | $1.69M 10-Q · filed 2015-08-14 | $1.34M 10-Q · filed 2014-08-14 | $2.35M derived: sum of 3 quarters · filed 2015-08-14 | $3.07M derived: sum of 4 quarters · filed 2015-08-14 | ||
| 2014-03-31 | $731.00K 10-Q · filed 2015-05-15 | $1.40M derived: sum of 2 quarters · filed 2015-05-15 | $2.11M derived: sum of 3 quarters · filed 2015-05-15 | $2.71M derived: sum of 4 quarters · filed 2015-05-15 | ||||
| 2013-12-31 | $667.68K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $1.38M derived: sum of 2 quarters · filed 2015-03-27 | $1.98M derived: sum of 3 quarters · filed 2015-03-27 | $2.78M 10-K · filed 2015-03-27 | ||||
| 2013-09-30 | $713.20K 10-Q · filed 2014-11-14 | $1.32M derived: sum of 2 quarters · filed 2014-11-14 | $2.11M 10-Q · filed 2014-11-14 | |||||
| 2013-06-30 | $603.05K 10-Q · filed 2014-08-14 | $1.27M 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |